Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT06742996
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT06735664
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 20
- Registration Number
- NCT06730542
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 56
- Registration Number
- NCT06697184
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06695013
- Locations
- 🇨🇳
Ruijin, Shanghai, Shanghai, China
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06669143
Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 42
- Registration Number
- NCT06647732
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06646666
- Locations
- 🇨🇳
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06637501
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Peoples Hospital of Changzhou, Changzhou, Jiangsu, China
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 170
- Registration Number
- NCT06634589
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.